- ATAI Life Sciences NV Announces Strategic Investment in Beckley Psytech Ltd Call TranscriptJan 04, 2024
- Q3 2022 ATAI Life Sciences NV Earnings Presentation TranscriptNov 10, 2022
- ATAI Life Sciences NV R&D Investor Day TranscriptOct 25, 2022
- ATAI Life Sciences NV at Citi BioPharma Conference TranscriptSep 07, 2022
- Q2 2022 ATAI Life Sciences NV Earnings Presentation TranscriptAug 15, 2022
- ATAI Life Sciences NV at Citi Biopharma Co-Panel Day (Virtual) TranscriptMay 18, 2022
- Q1 2022 ATAI Life Sciences NV Earnings Call TranscriptMay 16, 2022$4.04 (+10.99%)Earnings
- Q4 2021 ATAI Life Sciences NV Earnings Call TranscriptMar 30, 2022$5.34 (-1.48%)Earnings
- ATAI Life Sciences NV at Citi Winter Biotech Virtual Bus Tour TranscriptMar 22, 2022
- Atai Life Sciences N.V. - Special Call TranscriptJan 18, 2022
- Q3 2021 ATAI Life Sciences NV Earnings Call TranscriptNov 15, 2021$12.85 (-13.87%)Earnings
- ATAI Life Sciences NV at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 11, 2021
- ATAI Life Sciences NV at Citi BioPharma Conference (Virtual) TranscriptSep 08, 2021
ATAI Life Sciences NV R&D Investor Day Transcript
Good morning, everyone. I'm Florian Brand, the Co-Founder and CEO of atai Life Sciences, and it's a pleasure to welcome you today to our R&D Day.
We have an incredible agenda today, and we'll hear from industry key opinion leaders and some of our own senior R&D team. To kick things off, I'll walk you through our founding story and how we anticipate making a positive impact for mental health patients. Then we will deep dive into one of our key indications, treatment-resistant depression, or TRD.
We'll start with an engaging fireside chat hosted by Dr. Heather Berlin, in which he will discuss the clinical and regulatory aspects of TRD with Dr. Gerard Sanacora and Heddie Martynowicz.
Then our Co-Founder and Chief Scientific Officer, Dr. Srinivas Rao, will discuss PCN-101, our R-ketamine program in TRD. This program has a Phase IIa readout coming up around the end of this year. Srini will focus on contextualizing this specific upcoming dataset. He will then briefly discuss COMP360, a psilocybin therapy program
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)